DexCom, Inc. DXCM
81.79 USD +1.45 (+1.80%)
Nov 12, 2026, 2:09 PM EST
79.38 Day range 82.51
57.56 52-week range 92.34
- YTD
- +23.23%
- 1 year
- +37.21%
News
businesswire.com Dexcom Announces Upcoming Conference Presentation SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Jefferies Global Healthcare Conference in London on Tuesday,…
benzinga.com Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97 Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.
benzinga.com JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85 JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $82 to $85.
benzinga.com Barclays Maintains Overweight on DexCom, Raises Price Target to $120 Barclays analyst Christopher Pasquale maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $115 to $120.
benzinga.com StoneX Maintains Buy on DexCom, Raises Price Target to $93 StoneX analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $93.
benzinga.com DexCom Q3 2026 Earnings Call Transcript DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com DexCom Raises FY2026 Sales Guidance from $5.180B-$5.250B to $5.200B-$5.250B vs $5.229B Est DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.180 billion-$5.250 billion to $5.200 billion-$5.250 billion vs $5.229 billion estimate.- benzinga.com DexCom Announces Availability Of Dexcom G7 15 Day Continuous Glucose Monitoring System In Canada From November DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next…
benzinga.com Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 13.07% on an annualized basis producing an average annual return of 26.01%. Currently, DexCom has a market capitalization of…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65 Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology,…
benzinga.com BTIG Maintains Buy on DexCom, Raises Price Target to $96 BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $96.
benzinga.com Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115 Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweight rating and announces Price Target of $115.
benzinga.com Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.- benzinga.com RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105 RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $105.
benzinga.com The Insider Report: The Leaders Have Taken Off Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and…- benzinga.com Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s…
- benzinga.com Truist Securities Maintains Buy on DexCom, Raises Price Target to $102 Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.
benzinga.com FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.- benzinga.com Argus Research Maintains Buy on DexCom, Raises Price Target to $96 Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.
- benzinga.com Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90 Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.
- benzinga.com Citigroup Maintains Buy on DexCom, Raises Price Target to $88 Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $84 to $88.
benzinga.com RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90 RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.- benzinga.com Mizuho Maintains Outperform on DexCom, Raises Price Target to $95 Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $95.
benzinga.com Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.- benzinga.com JP Morgan Maintains Neutral on DexCom, Raises Price Target to $82 JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $65 to $82.
- benzinga.com Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95 Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.
- benzinga.com Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90 Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $85 to $90.
benzinga.com AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.- benzinga.com Stifel Maintains Buy on DexCom, Raises Price Target to $95 Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $95.
- benzinga.com Benchmark Maintains Buy on DexCom, Raises Price Target to $82 Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $77 to $82.
- benzinga.com Truist Securities Maintains Buy on DexCom, Raises Price Target to $93 Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $87 to $93.
- benzinga.com BTIG Maintains Buy on DexCom, Raises Price Target to $90 BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $80 to $90.
- benzinga.com DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.
- benzinga.com DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per…
- benzinga.com DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data.…
- benzinga.com Truist Securities Maintains Buy on DexCom, Raises Price Target to $87 Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $80 to $87.
benzinga.com Mizuho Maintains Outperform on DexCom, Raises Price Target to $90 Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.- benzinga.com Dexcom Receives Health Canada Authorization For Dexcom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5.Dexcom, Inc.…
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.- benzinga.com Deutsche Bank Initiates Coverage On DexCom with Buy Rating, Announces Price Target of $86 Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating and announces Price Target of $86.
- benzinga.com Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years
benzinga.com Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time Glucose Monitoring.- benzinga.com Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88 Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $75 to $88.
- benzinga.com FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children
- benzinga.com TD Cowen Maintains Buy on DexCom, Raises Price Target to $95 TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $75 to $95.
benzinga.com Earnings Scheduled For April 30, 2026 
benzinga.com Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising competition and past share losses.
benzinga.com GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech GlucoTrack targets a Q2 2026 FDA IDE filing for CGM, backed by clinical data, manufacturing strategy, and reimbursement pathway.
benzinga.com Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday? After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expected inflation print reinforced expectations for interest-rate cuts during the year.